McKinnon P, Ross M, Wells J R, Ballard F J, Francis G L
Department of Biochemistry, University of Adelaide, South Australia.
J Mol Endocrinol. 1991 Jun;6(3):231-9. doi: 10.1677/jme.0.0060231.
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells. The constructs encoding the signal peptide, sequence of the mature peptide and a C-terminal extension peptide were expressed under the control of a Rous sarcoma virus promoter. Successfully transfected clones secreting correctly processed recombinant hIGF-I or des(1-3)IGF-I were selected by their secretion of IGF-I-like activity into the culture medium. The recombinant peptides were purified to homogeneity as assessed by high-performance liquid chromatography and N-terminal sequence analysis. The purified recombinant peptides exhibited biological potencies equivalent to authentic IGF-I and des(1-3)IGF-I respectively.
重组人胰岛素样生长因子-I(hIGF-I)和一种缺乏N端三肽的生物活性变体(des(1-3)IGF-I)是由转染的中国仓鼠卵巢细胞产生的。编码信号肽、成熟肽序列和C端延伸肽的构建体在劳斯肉瘤病毒启动子的控制下表达。通过向培养基中分泌IGF-I样活性,筛选出成功转染并分泌正确加工的重组hIGF-I或des(1-3)IGF-I的克隆。通过高效液相色谱和N端序列分析评估,重组肽被纯化至同质。纯化后的重组肽分别表现出与天然IGF-I和des(1-3)IGF-I相当的生物活性。